Forward
Techno-Blast
Friday, January 20, 2017  |  Volume 9 / Number 2  |  A Production of the BioProcessing Journal
ISBioTech 7th Spring Meeting
Career Development
CASSS
CMC Strategy Forum
January 23, 2017
WCBP
January 24–26, 2017
Washington, DC USA
Disposable Solutions
Disposable Solutions for Biomanufacturing
February 27–March 1, 2017
Munich, Germany
International Serum Industry Association
12th Annual Meeting
May 3–4, 2017
Hong Kong
ASGCT
20th Annual Meeting
May 10–13, 2017
Washington, DC USA
25th ESACT Meeting
25th ESACT Meeting
May 14–17, 2017
Lausanne, Switzerland
ISBioTech 5th Fall Meeting
Techno-Blast Masthead
A sub-confluent culture of iCell® Endothelial Cells fixed and immunostained for the cell-cell contact protein beta-catenin (green) and tubulin (red).
Courtesy of Cellular Dynamics International, a FUJIFILM company.
Suggested Reading
From The Editor-in-Chief
Current and Future Lentiviral Vector Production Technologies
By Keith L. Carson, ChE, MBA, BioProcessing Journal
Discuss on LinkedIn
LinkedIn
Products & Services
Next Generation in Cell Separation
The Quad Technologies MagCloudz™ Streptavidin Cell Separation kit featuring QuickGel™ technology enables time saving, easy to execute cell isolation with complete magnetic particle release. This unique cell separation approach results in label-free, highly viable purified cells in their native state, allowing them to be cultured and proliferated downstream.
QuickGel™
The unique QuickGel technology instantly dissolves and releases target cells following the isolation procedure. Efficient cell release results in highly pure and viable isolated cells suitable for downstream culture, assays, and functional studies. Cellular phenotype is preserved, leaving cells healthy for scalable research applications in areas such as T-cell therapy and immunotherapy. The ability to use a biotinylated antibody of choice allows the MagCloudz kit to be used across a range of target cell types.

For more information, please visit quadtechnologies.com.
First Commercial Service to Predict Multiple Sources of DNA Damage
MilliporeSigma has introduced CAN FlowScreen™ screening services to more accurately predict genotoxic and mode of action properties of substances, ingredients, and drug compounds. Offered through its BioReliance® testing facilities, MilliporeSigma will be the first company to provide this service in the United States.

The screening process uses flow cytometry to quickly and efficiently screen for clastogens, aneugens, and non-genotoxicants (CAN). The results from the assay can help manufacturers reject harmful substances during product development or reduce undesirable properties at an early stage.
The CAN FlowScreen assay analyses multiple biomarkers (p53, hH2AX, and Phospho-Histone H3) associated with DNA damage in a single high-throughput assay. This model provides accurate predictions of genotoxicity to help avoid false positives or other misinformation that may exclude an otherwise safe compound from a development pipeline. The CAN FlowScreen assay uses a minimal amount of material for testing and provides rapid results.

The CAN FlowScreen assay is based on kits from Litron Laboratories. For more information, please visit bioreliance.com.
CAN FlowScreen™
Development of CAR T-Cell Therapy Manufacturing Platform
Servier and MaSTherCell SA announce the signing of a master service agreement for the development of a manufacturing platform for allogeneic cell therapies. Under the agreement, MaSTherCell is developing a CAR T-cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier cell therapy products. This is a critical step in development of these products for later stage clinical trials.
Manufacturing
Servier selected MaSTherCell because of its position as a leading global cell therapy contract development and manufacturing organization (CDMO) as well as its essential broad expertise in immunotherapy products. MaSTherCell has a track record of designing and delivering cost-effective cell therapy manufacturing platforms, and anticipates that it will complete the development of the initial CAR T-cell platform in 2018. This will be an efficient complement to the bioproduction facilities that Servier is developing at its site in Gidy, France which will focus mainly on the production of antibodies.

For more information, please visit masthercell.com.
Career Development
FDA
Public Workshop
Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products
February 8–9, 2017
College Park, Maryland USA
BioProcess Cuba
BPJ Publishing
Now Offers Open Access
BioProcessing Journal BioProcessing Journal
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Request a media kit today!
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]